Company: PCRX
Filing Date: 2025-04-07
Form Type: 8-K
Source: 0001396814-25-000051
Chunk: 1

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-07
Form: 8-K
Item: Item 1.01
Chunk 1
---
 low thirties in 2033 and increasing modestly in each of the next two 12-month periods before reaching a maximum percentage in the high thirties of the total volumes distributed in the U. S. for the final three years of the agreement. In addition, the Company has agreed to provide the Fresenius Parties with a license to the Company’s patents required to manufacture and sell an unlimited quantity of a generic bupivacaine liposome injectable suspension in the U. S. beginning on a confidential date in 2039.

In addition, in recognition of the Company’s expected savings with respect to, among other things, the avoidance of the fees, costs, time and resources associated with continuing the Litigations, the Company will pay the Fresenius Parties $7.0 million.

The foregoing description of the Settlement Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Settlement Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarterly period ending March 31, 2025.